- CEM Corporation announced the launch of a new series of products that can significantly change the peptide synthesis paradigm from early detection of preclinical research
- Liberty blue technology allows a four minute cycle, and the amount of solvent is reduced by 90% compared with the existing peptide development methods
- CEM Corporation, headquartered in Matthews, North Carolina, is a leading global company focusing on scientific solutions for critical experimental applications
CEM Corporation announced the launch of a new series of products that can significantly change the peptide synthesis paradigm from early detection of preclinical research
Liberty blue (TM) series research scale microwave peptide synthesis system and liberty XL (TM) medium-sized microwave peptide synthesis system were favored by the participants at the 23rd American peptide Conference on June 23.
Matthews, North Carolina June 24, 2013 / AP / — CEM Corporation, a leading global supplier of microwave testing instruments, is pleased to announce the launch of a new series of products that can significantly change the peptide synthesis paradigm from early detection in preclinical research.
Liberty Blue Gamma Research on the synthesis of XL peptides by microwave system Gamma The medium-sized microwave peptide synthesis system was favored by the participants at the 23rd American peptide Symposium in Hawaii on June 23 (Sunday).
Liberty blue technology allows a four minute cycle, and the amount of solvent is reduced by 90% compared with the existing peptide development methods
The technology significantly improves hardware design and chemical processes, resulting in higher speed and flexibility, peptide purity and yield, and stability.
“This is a revolutionary technology that will revolutionize peptide synthesis,” said Michael J. Collins, President and CEO of CEM Corporation. It will provide unprecedented capacity for the whole process of peptide synthesis, from the pilot optimization to the establishment of target peptide library, until the production of 200 grams of preclinical research
Collins continued: “the cycle is 10 times faster than current microwave synthesis, allowing pharmacists to make normal peptides in less than an hour. In addition, even if the cycle is accelerated, the purity of peptides produced by these new microwave peptide synthesis systems is still unparalleled. “
The patent of the system is pending flex add Gamma The technology provides unlimited delivery with high accuracy and precision, enabling liberty blue series to cover a large-scale range of 0.025 to 5 mmol, which is the largest research scale of microwave peptide synthesis system. In addition, the chemical process can be upgraded directly to 100 mmol with the new liberty XL.
Liberty blue series microwave peptide synthesis systems focus on achieving high speed, high efficiency and ease of use, including manual, automatic and high flux systems, while liberty XL is a medium-sized automatic system. These systems all use the microwave energy of the linking and deprotection steps in the synthesis process of CEM, and use patented technology, which can ensure higher purity and yield faster than before.
Collins concluded: “we expect liberty blue and liberty XL to have a greater impact on peptide synthesis than when we first launched our microwave peptide technology, which has become a choice for many researchers. These new products will give pharmacists a chance to break through the restriction of peptide synthesis once again. “
CEM Corporation, headquartered in Matthews, North Carolina, is a leading global company focusing on scientific solutions for critical experimental applications
The company has branches in the UK and Ireland, Germany, Italy, France and Japan, and has a global network of distributors.
CEM designs and manufactures systems for bioscience applications, life sciences, analytical laboratories and processing plants worldwide. The company’s products are used in many industries, including pharmaceuticals, biotechnology, chemistry and food processing, as well as academic research.